Fortress Biotech (FBIO) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fortress Biotech (FBIO) has outperformed Rein Therapeutics (RNTX) over the past year, losing 28.2% versus a loss of 44.7%. Over five years, FBIO leads with a -95.5% price change compared with -96.2% for RNTX. Fortress Biotech is the larger company by market cap ($69.7 million vs $66.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | RNTX |
|---|---|---|
| Share price | $2.09 | $0.7693 |
| Market cap | $69.70M | $66.37M |
| 1-day change | +2.45% | -2.46% |
| YTD return | -42.90% | -33.68% |
| 1-year return | -28.18% | -44.65% |
| 5-year return | -95.48% | -96.19% |
| P/E ratio (TTM) | 0.76 | — |
| EPS (TTM) | $2.76 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.53 | $2.18 |
| 52-week low | $2.00 | $0.694 |
| Distance from 52-week high | -53.86% | -64.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +139.23% | +679.93% |
| Average volume | 495.05K | 430.81K |
| Shares outstanding | 33.35M | 86.27M |
| Employees | 78 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed RNTX by 16.5 percentage points over the past year.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Healthcare · Biotechnology · 78 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Healthcare · Biotechnology · 10 employees
FBIO vs RNTX FAQ
Which is bigger, Fortress Biotech or Rein Therapeutics?
Fortress Biotech (FBIO) is larger, with a market capitalization of $69.70M compared with $66.37M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, FBIO or RNTX?
FBIO returned -28.18% over the past 12 months, compared with -44.65% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.